Long-term response to sunitinib therapy for metastatic renal cell carcinoma Journal Article
| Authors: | Molina, A. M.; Jia, X.; Feldman, D. R.; Hsieh, J. J.; Ginsberg, M. S.; Velasco, S.; Patil, S.; Motzer, R. J. |
| Article Title: | Long-term response to sunitinib therapy for metastatic renal cell carcinoma |
| Abstract: | Background: Sunitinib achieves objective response and prolongs progression-free survival (PFS) in patients with metastatic renal cell carcinoma (RCC). A subset of patients achieves long-term responses. The characteristics of patients who achieved long-term response (defined as patients achieving ongoing complete response [CR] or remaining progression free for > 18 months while receiving sunitinib) are reported. Patients and Methods: A database of 186 patients treated with sunitinib alone (n = 89) or in combination (n = 97) in 9 clinical trials was reviewed; all had 1 year or more follow-up from sunitinib start to data cutoff for analysis. Median PFS was 10.8 months (95% CI, 8.3-13.3); median overall survival (OS) was 30.4 months (95% CI, 21.5-36.8 months) for the 186 patients. Thirty-four patients were identified as long-term responders because they either had durable CR or remained progression free while receiving sunitinib for > 18 months. Results: Best response for 34 long-term responders was CR in 3 patients, partial response (PR) in 24 patients, and stable disease in 7 patients. The median duration of sunitinib therapy was 24.9 months (range, 18.1-73.9 months). The median PFS among the long-term responders was 17.4 months (95% CI, 7-29.9 months) at a landmark PFS analysis performed after 18 months from treatment start. Univariate analysis from the 186 patients identified bone metastasis, lung metastasis, and intermediate/poor risk groups as adverse prognostic factors for long-term response. Conclusion: Sunitinib achieves long-term response in a subset of patients with metastatic RCC. Lack of bone metastasis or lung metastasis and good MSKCC risk status may predict long-term response. © 2013 Elsevier Inc. |
| Keywords: | adult; cancer chemotherapy; treatment response; aged; major clinical study; overall survival; fatigue; neutropenia; sunitinib; diarrhea; hypertension; hypophosphatemia; side effect; systemic therapy; bone metastasis; cancer patient; follow up; progression free survival; drug eruption; anemia; bleeding; nausea; vomiting; retrospective study; risk factor; renal cell carcinoma; drug fever; lymphocytopenia; lung metastasis; targeted therapy; high risk population; hand foot syndrome; kidney metastasis; proteinuria; metastatic |
| Journal Title: | Clinical Genitourinary Cancer |
| Volume: | 11 |
| Issue: | 3 |
| ISSN: | 1558-7673 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2013-09-01 |
| Start Page: | 297 |
| End Page: | 302 |
| Language: | English |
| DOI: | 10.1016/j.clgc.2013.04.001 |
| PROVIDER: | scopus |
| PUBMED: | 23707221 |
| PMCID: | PMC3959735 |
| DOI/URL: | |
| Notes: | --- - "Export Date: 1 October 2013" - "Source: Scopus" |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work